Chronic Kidney Disease (CKD) affects over 800 million individuals worldwide. One of the challenges with CKD is its insidious nature; kidneys can compensate for up to 80% functional loss before symptoms manifest. Early detection and preventative medication are crucial, particularly for reducing cardiovascular risks.
Statins: Lower LDL, Increased Protection
The current KDIGO guidelines recommend statins for CKD patients based primarily on their cardiovascular risk, rather than solely on LDL cholesterol levels. For patients over 50 years old who are not receiving renal replacement therapy, statin use is generally indicated. For younger patients under 50, therapy may be considered if additional risk factors such as diabetes, hypertension, or albuminuria are present.
Atorvastatin is often preferred in these cases. It’s important to note that with Rosuvastatin, only 10 mg per day is permitted if the creatinine clearance is below 30 ml/min. Caution is advised regarding interactions with macrolides, azole antifungals, or ciclosporin; using it in combination with gemfibrozil is contraindicated.
Interestingly, researchers from the Weizmann Institute have uncovered an unexpected side effect: Sildenafil may slow cholesterol assimilation in cancer cells, a process that statins enhance. Statistical analyses suggest a better survival rate among cancer patients who utilized both drug classes.
New Approvals: Atrasentan and Obicetrapib
Pharmacotherapy for kidney patients is advancing. On April 2, 2025, the selective ETA antagonist Atrasentan received FDA approval for treating primary IgA nephropathy. The medication is administered at a daily dose of 0.75 mg and aims to reduce proteinuria. The Phase-3 ALIGN study is expected to run until mid-December 2026.
Moreover, the CHMP has released a favorable opinion on Obicetrapib and its fixed combination with Ezetimibe for lipid management. Phase-3 studies have shown an LDL-C reduction of up to 40% with monotherapy and up to 50% in combination therapy. The EU Commission’s decision is expected in the second half of 2026.
A meta-analysis published in JAMA in July 2026 emphasizes the value of combination therapies. An evaluation of data from 159,000 participants indicated that fixed combinations of sartans and calcium channel blockers reduce the risk of treatment discontinuation by 39%. Comparatively, sole calcium channel blockers or combinations of beta-blockers and thiazide diuretics fared much worse.
Research: STAREE Study and Cardio-CT
Exciting results are anticipated from the STAREE study, which examines the use of 40 mg Atorvastatin in over 9,900 seniors aged 70 and older. This study aims to clarify the influence on cardiovascular events and survival rates free of dementia or disabilities. Results are set to be presented at the ESC Congress in late August 2026.
In diagnostics, Cardio-CT has established itself as the primary instrument when coronary artery disease is suspected. It offers high diagnostic accuracy and is deemed cost-effective. However, its application may be limited in individuals with severe kidney dysfunction due to the required contrast agents.
Transplantation: Successful Third Kidney Transplant
Despite the advancements in medication, transplantation remains the most effective treatment for terminal kidney failure. In late July 2026, a medical breakthrough occurred in Vietnam where a 57-year-old patient with vascular anomalies successfully received a third kidney transplant. This case highlights surgical possibilities in complex pre-existing conditions, although long-term survival rates for multiple transplants are lower. Experts estimate a five-year survival rate post third transplant to be around 55% to 70%.
In conclusion, the landscape of CKD management continues to evolve, with significant findings in pharmacotherapy and diagnostics. The combination therapies showing reduced treatment discontinuation risks highlight the need for personalized approaches in managing chronic conditions effectively.
